Reimbursed Care Access in Western Sahara

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. In practice, legal enforcement in the territory is governed by Moroccan law in Moroccan-administered areas and by SADR/Polisario regulations in Polisario-controlled camps; neither framework provides for reimbursed medical psilocybin access. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Western_Sahara?utm_source=openai))

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no publicly available evidence of authorized, reimbursed MDMA-assisted therapy programs operating in Western Sahara or of national reimbursement pathways. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Western_Sahara?utm_source=openai))

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no publicly available record of esketamine (Spravato®) marketing authorization or a national reimbursement pathway for esketamine in Western Sahara; medical regulatory and reimbursement matters in Moroccan-administered areas follow Moroccan health authorities while SADR-administered areas use their own decrees. (Note: esketamine has regulatory approvals in some other jurisdictions such as the U.S. FDA, but no documentation was found indicating a Moroccan/SADR approval or reimbursement program for Western Sahara). ([en.wikipedia.org](https://en.wikipedia.org/wiki/Western_Sahara?utm_source=openai))

Ketamine is an established anesthetic and analgesic on the World Health Organization’s Essential Medicines list and is therefore routinely used in medical settings worldwide for anesthesia and emergency medicine; where conventional medical services operate (i.e., Moroccan-administered hospitals/clinics in Western Sahara), ketamine would be expected to be available for licensed medical indications under standard medical practice and hospital formularies. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Ketamine-assisted_psychotherapy?utm_source=openai))

Medical/reimbursement context (practical implications for Western Sahara):
- Regulatory/administrative authorities: In parts of Western Sahara administered de facto by Morocco, drug regulation, hospital formularies, and public/private reimbursement are governed by Moroccan national authorities and health system rules; Moroccan hospitals follow national drug regulation and procurement processes for essential anesthetics such as ketamine. In Polisario-administered camps and SADR-controlled areas, health services are run under SADR/Polisario structures and international humanitarian health actors, and operate under different legal/administrative arrangements. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Western_Sahara?utm_source=openai))

- Indications & reimbursement: Ketamine’s primary approved/standard uses are anesthetic and analgesic; psychiatric uses (e.g., repeated subanesthetic ketamine for depression) are considered off-label in many jurisdictions even where administered clinically. There is no evidence of a formal, reimbursed ketamine-for-psychiatric-disorders program specific to Western Sahara; any psychiatric use would be off-label clinical practice and depend on local facility policies, availability, and payer arrangements in Moroccan-administered areas or on NGO/humanitarian providers in SADR areas. Where national public insurance exists under Moroccan administration, reimbursement for off-label psychiatric ketamine is unlikely without a formal national program. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Ketamine-assisted_psychotherapy?utm_source=openai))

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. No authorized, reimbursed medical DMT programs or legal pathways for clinical access in Western Sahara were identified. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Western_Sahara?utm_source=openai))

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no evidence of regulated clinical access or reimbursement for 5‑MeO‑DMT in Western Sahara. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Western_Sahara?utm_source=openai))

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. No legal, reimbursed ibogaine treatment programs are documented for Western Sahara. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Western_Sahara?utm_source=openai))

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Traditional plant brew uses (ayahuasca) are not provided for under national reimbursement schemes in Western Sahara; possession/use is within the same controlled‑substance enforcement frameworks described above. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Western_Sahara?utm_source=openai))

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no documented medical or reimbursed access pathway for mescaline in Western Sahara. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Western_Sahara?utm_source=openai))

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. No legal medical or reimbursement frameworks for 2C‑series phenethylamines are available in Western Sahara. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Western_Sahara?utm_source=openai))